Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors

Rubinfeld expected to assist with FDA approval process for autologous cultured skin substitute, PermaDerm(TM)

NEW YORK, August 24, 2010 - Regenicin, Inc. (www.regenicin.com) (OTC Bulletin Board: WDSTD), a
clinical-stage biotechnology company, announced today that Dr. Joseph
Rubinfeld, one of the four original founders of Amgen, Inc.
(www.amgen.com), has agreed to join the company's board of directors.
Dr. Rubinfeld will be instrumental to assisting the company's
commercialization efforts of PermaDerm(TM), Regenicin's proprietary
autologous (www.regenicin.com/about-permaderm.html) cultured skin
substitute intended to restore the qualities of healthy human skin for use in
the treatment of burns, chronic wounds and a variety of plastic surgery
procedures.

In addition to his efforts in founding Amgen, Dr. Rubinfeld has a
forty-year history in pharmaceutical and consumer product development. His
accomplishments include the creation of the multi-billion dollar antibiotic
Amoxicillin as well as the first synthetic biodegradable detergent. He has
obtained over 100 patents during his distinguished career.

Commenting on his decision to join Regenicin, Dr. Rubinfeld stated, "With
the recent acquisition of the rights to this revolutionary technology,
Regenicin is in a position to be the only company in the world capable of
quickly growing and grafting a person's own skin. This is a critical
development for the multi-billion dollar treatment market for burns and other
wounds that are currently dependent on cadaver and pig skin," said Dr.
Rubinfeld. "These methods often have high rejection rates compared to
virtually no rejection issues when a person's own skin is being used for
grafting. I look forward to helping the team at Regenicin navigate through
the final hurdles toward commercialization of this life improving
technology."

Dr. Rubinfeld began his career as a research scientist with several
pharmaceutical and consumer product companies including Schering Plough and
Colgate Palmolive. He served for 12 years at Bristol Myers, where in addition
to developing Amoxicillin and Chephadroxil, he was instrumental in licensing
their original anti-cancer line of products, including Mitomycin, Etoposide,
and Bleomycin. After co-founding Amgen in 1980 and serving as its chief of
operations, Dr. Rubinfeld has served as an advisor or Board member to a
number of companies including AVI BioPharma and Quark Pharmaceuticals. In
1991 he co-founded Supergen, a drug development company based in Dublin,
California, where he served as President and CEO until 2003 and as a member
of the Board of Directors until 2005. During that time he oversaw the
company's initial public offering and its rise to a multi-billion dollar
market capitalization. Management believes his wealth of experience in
biotech and big pharma will be instrumental for Regenicin as it transitions
to commercialization.

"We are honored to have Dr. Rubinfeld join our board," said Randall
McCoy, Chief Executive Officer, Regenicin. "His expertise in regulatory
product approval processes and subsequent commercialization will prove
invaluable to Regenicin as we enter this new phase in our company's history
and bring PermaDerm(TM) to patients worldwide."

About Regenicin, Inc.

Regenicin, Inc. (www.regenicin.com) is a clinical-stage company
developing next-generation tissue-engineered skin substitutes to restore the
qualities of healthy human skin. Regenicin is a publicly traded company, with
headquarters in New York, NY. Additional information can be found on the
company's website, www.regenicin.com and in the company's filings with
the Securities and Exchange Commission located at www.sec.gov.

Jay Strell, Sunshine, Sachs and Associates, strell at sunshinesachs.com, +1-212-691-2800, for Regenicin, Inc.